High-fat diet (HFD) and inflammation are key contributors to insulin resistance and type 2 diabetes (T2D). Interleukin (IL)-1b plays a role in insulin resistance, yet how IL-1b is induced by the fatty acids in an HFD, and how this alters insulin signaling, is unclear. We show that the saturated fatty acid palmitate, but not unsaturated oleate, induces the activation of the NLRP3-ASC inflammasome, causing caspase-1, IL-1b and IL-18 production. This pathway involves mitochondrial reactive oxygen species and the AMP-activated protein kinase and unc-51-like kinase-1 (ULK1) autophagy signaling cascade. Inflammasome activation in hematopoietic cells impairs insulin signaling in several target tissues to reduce glucose tolerance and insulin sensitivity. Furthermore, IL-1b affects insulin sensitivity through tumor necrosis factor-independent and dependent pathways. These findings provide insights into the association of inflammation, diet and T2D.
A r t i c l e s
The incidence of type 2 diabetes (T2D) worldwide has increased markedly and constitutes one of the major threats to global health. Insulin resistance, a hallmark of T2D, is associated with low-grade systemic inflammation characterized by upregulated cytokine production and activated inflammatory signaling pathways 1 . Interleukin (IL)-1β is one of the principal inflammatory cytokines implicated in both type 1 diabetes and T2D. IL-1β mediates beta-cell destruction leading to type 1 diabetes 2 and elevates risk for T2D 3 by inducing insulin resistance in insulin-sensitive cells 4, 5 . Two recent clinical studies reported that either IL-1 receptor antagonist (IL-1RA) or IL-1β antibody can help treat T2D 6, 7 .
Despite evidence for a role of inflammatory mediators in insulin resistance, less is known about how these inflammatory mediators are generated. Recent studies implicate elevated glucose 8 and islet amyloid polypeptide 9 as key inducers of IL-1β generation and NLRP3 (nucleotide-binding domain, leucine-rich repeats containing family, pyrin domain-containing-3) 10 inflammasome activation in the pancreas. However, IL-1β-induced islet beta-cell dysfunction and apoptosis result after disease has already progressed from an initial insulin resistance condition to T2D 11 . Therefore, these studies cannot explain how IL-1β is generated during the early insulin-resistance phase, before T2D occurs.
The consumption of an HFD is an important factor contributing to T2D. Because free fatty acids (FFAs) in plasma are elevated in humans with T2D, as well as diabetic animals 12 , FFAs have been proposed to promote inflammatory responses by directly engaging toll-like receptors (TLRs) and inducing NF-κB-dependent production of inflammatory cytokines such as tumor necrosis factor (TNF) and 14) . In addition to TLRs, members of the NLR family are important in both innate and adaptive immunity, but their roles in response to FFAs have not been investigated 15 . Several NLR molecules including NLRP3, along with the adaptor protein ASC (apoptotic speck protein containing a caspase recruitment domain; also called PYCARD) and procaspase-1, form molecular platforms called the inflammasome, which mediates the catalytic activation of caspase-1, followed by the cleavage and release of proinflammatory cytokines IL-1β and IL- 18 (refs. 16,17) . Inflammasome activators include certain pathogens, endogenous markers of cellular damage (ATP and uric acid) and exogenous stressinducing agents (alum, asbestos and silica). In this study, we tested a working model in which FFA activates inflammasome-dependent IL-1β secretion from myeloid cells and this IL-1β release then impairs the physiological functions of insulin in insulin target organs.
RESULTS

Palmitate activates the NLRP3-ASC inflammasome
The production of the mature caspase-1 that is necessary for the processing and production of IL-1β and IL-18 requires two signals. The first, which induces the transcription and translation of pro-IL-1β and pro-IL-18, can be achieved by priming macrophages with various stimuli, including lipopolysaccharide (LPS) (Supplementary Fig. 1) . A second signal is required to activate the inflammasome to cause the autocatalytic cleavage of procaspase-1 to caspase-1.
Palmitate is one of the most abundant saturated fatty acids in plasma and is substantially elevated following an HFD 12 . We tested whether A r t i c l e s palmitate could serve as the second signal by exposing cells to LPS and then to palmitate conjugated to fatty acid-free bovine serum albumin (palmitate-BSA). This conjugation is needed to increase palmitate solubility. Palmitate-BSA, but not BSA alone, induced IL-1β from wildtype bone marrow-derived macrophages (BMMs) (Fig. 1a) . Without LPS, palmitate-BSA treatment of macrophages did not induce IL-1β, supporting the two-signal hypothesis of inflammasome activation. Palmitate-BSA-induced IL-1β and IL-18 secretion was also dose dependent (Fig. 1b,c) . In contrast to IL-1β production, IL-6 production was not significantly increased by palmitate-BSA (P = 0.169; Fig. 1d ), indicating specificity of the palmitate effect 18 . Palmitate-BSA did not induce IL-1β or IL-18 in macrophages deficient in NLRP3 (Nlrp3 −/− ), ASC (Pycard −/− ) or caspase-1 (Casp1 −/− ); another NLR gene, Nlrc4, had no effect (Fig. 1e,f) . Peritoneal macrophages and bone marrow-derived dendritic cells (BMDCs) produced similar outcomes (Supplementary Fig. 2 ). The pan-caspase inhibitor zVAD or caspase-1-specific inhibitor zYVAD abolished palmitate-BSA-induced IL-1β release (Fig. 1g) , and Casp1 −/− cells did not produce IL-1β in response to palmitate-BSA (Fig. 1h) . In contrast to their IL-1β release, wildtype, Nlrp3 −/− , Pycard −/− and Casp1 −/− macrophages generated similar amounts of TNF upon palmitate stimulation (Fig. 1i) .
To biochemically assess inflammasome activation, we assayed the cleavage maturation of pro-IL-1β and procaspase-1 by immunoblotting. LPS or palmitate-BSA alone did not cause procaspase-1 and pro-IL-1β processing to their mature forms, but the two combined did (Fig. 2a) . Mature IL-1β and caspase-1 were not observed in Nlrp3 −/− and Pycard −/− BMMs (Fig. 2a) but were observed in Nlrc4 −/− cells (Fig. 2b) . These results indicate that palmitate-induced inflammasome is dependent on NLRP3 and ASC. To determine the effect of unsaturated fatty acid, we treated wild-type BMMs with LPS followed by 0.5 mM oleate to match the dosage of palmitate used. IL-1β, IL-6 and TNF were not enhanced by LPS plus oleate (Supplementary Fig. 3 ).
Inflammasome activation involves AMPK-ROS signaling
Reactive oxygen species (ROS) are essential for inflammasome activation 17 . Treatment of macrophages with palmitate-BSA and LPS also induced ROS activation, and this was inhibited by (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC), a ROS inhibitor (Fig. 3a) . APDC also inhibited palmitate-BSA-induced IL-1β release (Fig. 3b) and caspase or IL-1β cleavage (Fig. 3c) in a dose-dependent manner as assessed by enzyme-linked immunosorbent assay (ELISA) and immunoblot analysis. Another ROS inhibitor, N-acetyl-cysteine, and an NAPDH oxidase inhibitor, diphenyleneiodonium, also inhibited IL-1β secretion in response to LPS plus palmitate-BSA (Fig. 3d) .
The AMP-activated protein kinase (AMPK) has emerged as an essential mediator of fatty acid metabolism 19 , and it suppresses ROS production by inhibiting the expression and function of NADPH oxidase 20 . AMPK has also been shown to have an anti-inflammatory function in macrophages 21 . Thus we tested whether AMPK plays a role during inflammasome activation by palmitate. We first assessed AMPK activation upon dual treatment of macrophages with palmitate-BSA and LPS. Palmitate-BSA or LPS alone had little effect, whereas the two together decreased phosphorylation of the AMPK-α subunit (Fig. 4a) . To assess whether diminished AMPK activity leads to ROS generation, we enhanced AMPK activity with a widely used pharmacological AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) 21 . AICAR reduced palmitate-BSA and LPSinduced ROS generation (Fig. 4b) A r t i c l e s Because ROS were required for inflammasome activation by palmitate (Fig. 3) and AMPK reduced palmitate-induced ROS generation, we next tested whether AMPK plays a role in palmitateinduced inflammasome activation. AICAR significantly decreased palmitate-induced IL-1β release (Fig. 4c) , without affecting that of IL-6 (Fig. 4d) . In agreement with the latter observation, the concentration of AICAR used did not cause cytotoxicity (data not shown). Immunoblot analyses showed that AICAR reduced the processing of procaspase-1 and pro-IL-1β (Fig. 4e) . Samples treated with AICAR showed enhanced phosphorylation of acetyl-CoA carboxylase (ACC), a well-defined substrate of AMPK, at Ser79, indicating that AICAR had the expected effect on the AMPK pathway.
As an alternate to the pharmacological approach to AMPK, we transfected macrophages with a constitutively active α1-subunit of AMPK 22 . In agreement with the observation of others that primary macrophages are difficult to transfect, only 46% of the BMMs were transfected as determined by the expression of the green fluorescent protein (GFP) encoded by a plasmid (Fig. 4f) . Despite this suboptimal transfection efficiency, introduction of constitutively active AMPK-α1 decreased IL-1β secretion by 50% (Fig. 4g) . Together, these findings reveal an AMPK-ROS signaling axis that regulates NLRP3-ASC-caspase-1 inflammasome activation in response to palmitate stimulation.
In contrast to the suppression by AMPK of PA-BSA-induced IL-1β production, activation of AMPK with AICAR did not affect IL-1β release induced by ATP, nigericin or alum, suggesting a specific contribution of AMPK inactivity to palmitate-mediated inflammasome activation (Supplementary Fig. 4a ). AICAR also did not affect IL-6 production in response to these same activators ( Supplementary Fig. 4b) . We further the effect during palmitate treatment of previously identified factors that activate the NLRP3 inflammasome 17 . Potassium efflux is an important upstream step for NLRP3 inflammasome activation 17 . In the presence of high K + (ref. 23 ), palmitate-induced IL-1β release was completely abolished, suggesting that K + efflux is needed for palmitate-induced inflammasome activation (Supplementary Fig. 4c ). In contrast, the actin polymerization inhibitor cytochalasin D, which affects phagocytosis, abolished IL-1β release stimulated by alum 23 , but not by palmitate ( Supplementary Fig. 4d ). Lysosome inhibitors (bafilomycin A, chloroquine and ammonium chloride) attenuated IL-1β release induced by the bacterium Francisella tularensis 24 , but not by palmitate ( Supplementary Fig. 4e,f) . Deficiency in the ATP receptor P2X7R abolished ATP-induced IL-1β release, but did not affect palmitateinduced IL-1β release (Supplementary Fig. 4g ). Therefore, palmitateinduced inflammasome activation involves potassium efflux, but not a cytochalasin D-sensitive, lysosomal pathway or P2X7R.
Palmitate affects autophagy and mitochondrial ROS via AMPK Our results indicate that palmitate inflammasome induction is distinct in that it uses the AMPK pathway, in contrast to inflammasome activation by pathogens or damage-associated molecular patterns. Thus, we further explored the mechanism of inflammasome activation that lies downstream of decreased AMPK phosphorylation and activity during palmitate plus LPS treatment. Recent studies of the inflammasome in myeloid cells suggest that inhibition of autophagy by pharmacological inhibitor or autophagy-related gene deletion results in mitochondrial ROS generation that activates the NLRP3 inflammasome 25, 26 . Studies in fatty acid metabolism in non-immune cells identified AMPK as a positive regulator of autophagy that directly phosphorylates and activates ULK1, the mammalian homolog of autophagy-related-1 (Atg1) 27, 28 , which is essential for autophagosome formation 29 . Blockage of autophagy during metabolism can lead to increased ROS. Thus ROS activation and autophagy are similarly evoked in both inflammasome activation in myeloid cells and fatty acid metabolism in non-immune cells. The following experiments assessed whether fatty acid affects autophagy and mitochondrial ROS in macrophages, which would be expected to cause inflammasome activation, and whether AMPK regulates these two events.
We first tested whether reduced AMPK activity caused by palmitate plus LPS treatment leads to attenuated autophagy and mitochondrial ROS generation. During autophagy, microtubule-associated protein 1 light chain 3 (LC3) is converted from a cytosolic form (LC3-I) to a lipidated, membrane-associated form (LC3-II) and shows a punctate appearance 30 . We measured autophagosome formation by monitoring light chain 3β (LC3B) conversion by immunoblot, punctate appearance by immunofluorescence staining and direct observation of autophagosomes by transmission electron microscopy (TEM). LC3B-II was normalized to β-actin as the preferred way of measuring autophagy 30 . LPS treatment increased LC3B-II relative to β-actin (Fig. 5a) , promoted endogenous LC3B punctate staining (Fig. 5b) and resulted in more autophagosomes (Fig. 5c) , indicating that LPS induced autophagy, in agreement with a previous study 31 . In contrast, LPS-enhanced autophagosome formation was reversed by palmitate treatment (Fig. 5a-c) . Chloroquine, a widely used protease inhibitor, could not restore palmitate-diminished LC3B-II (Fig. 5a) , suggesting that palmitate-diminished autophagic activity is due to a decreased autophagosome synthesis, but not an increased degradation of autophagic substrates inside the autolysosome 29 .
Because reduction of LC3B-II upon LPS plus palmitate stimulation was accompanied by decreased phosphorylation of the AMPK-α subunit (Fig. 5a) , we determined whether AMPK could regulate autophagic activity. AICAR, which enhanced the phosphorylation of AMPK and its downstream target molecule ACC (Figs. 4e and 5d) , increased the punctate appearance of LC3B (Fig. 5b) and the number of autophagosomes (Fig. 5c) . It also induced the phosphorylation of ULK1 at Ser467 and Ser555 (Fig. 5d) , consistent with a recent discovery in non-immune cell types 27 . Notably, AICAR restored the amount of LC3B-II protein (Fig. 5d) . Therefore, palmitate-induced AMPK inactivation was associated with decreased autophagic activity marked by decreased LC3B-II, reduced LC3B punctation and number of autophagosomes, and reduced ULK1 phosphorylation, all of which could be rescued by the addition of the AMPK agonist AICAR. 
A r t i c l e s
We next assessed whether palmitate signaling through AMPK leads to the accumulation of mitochondrial ROS, which can activate the NLRP3 inflammasome 25, 26 . Treatment of BMMs with LPS plus palmitate significantly increased mitochondrial ROS as judged by MitoSox staining, and this was abolished by the AMPK agonist AICAR (Fig. 5e) . These data together suggest that treatment with palmitate plus LPS inhibits AMPK, which then blocks autophagy but enhances mitochondrial ROS, both of which are linked to inflammasome activation.
Palmitate-induced IL-1b impairs insulin signaling in vitro
Clinical studies of T2D suggest that elevated free fatty acids and IL-1β in the plasma promote insulin resistance 32, 33 . Therefore, we first sought to determine whether palmitate-induced NLRP3-ASC inflammasome-dependent IL-1β production inhibits insulin signaling in vitro. Because the liver is one of the main target organs of insulin, we used FL38B, a mouse liver cell line 34 , to test insulin signaling in vitro as reflected by the phosphorylation of the serine-threonine kinase Akt. Both phospho-flow cytometric (Fig. 6a) and immunoblot (Fig. 6b) analyses using an antibody to phosphorylated Akt showed that IL-1β treatment significantly dampened insulin-induced Akt phosphorylation (Fig. 6a,b and Supplementary Fig. 1 ). TNF is another proinflammatory cytokine that is essential for obesity-associated chronic inflammation and insulin resistance 35, 36 . Indeed, TNF treatment decreased insulin-induced Akt phosphorylation to an extent comparable to that of IL-1β (Fig. 6b) . Both TNF and IL-1β markedly enhanced the phosphorylation of insulin receptor substrate-1 (IRS1) at Ser307 (Fig. 6c) , a modification that has been shown to inhibit insulininduced phosphatidylinositol-3-OH kinase-Akt activation, resulting in insulin resistance 35 . These findings suggest that both TNF and IL-1β inhibit insulin signaling in an in vitro culture system.
To assess the link between NLRP3-ASC-caspase-1 inflammasome and insulin signaling, we stimulated LPS-primed wild-type, Nlrp3 −/− , Pycard −/− or Casp1 −/− BMMs with palmitate and collected the supernatant (conditioned medium; Fig. 6d,e) . Treatment of FL38B cells with conditioned medium generated from wild-type BMMs significantly inhibited insulin-induced Akt phosphorylation. However, Nlrp3 −/− , Pycard −/− or Casp1 −/− conditioned medium did not significantly affect insulin-induced Akt phosphorylation, suggesting that NLRP3-ASCdependent soluble factor(s) impaired insulin signaling (Fig. 6d,e) . We also observed the same effects as described above when using primary hepatocytes isolated from wild-type mice as insulin target cells (Fig. 6f  and Supplementary Fig. 1 ). To assess whether the soluble factor in wildtype conditioned medium was IL-1β, we added anakinra, an IL-1RA-based antagonist of IL-1 function, to wild-type conditioned medium. Anakinra partially restored insulin signaling as measured by Akt phosphorylation, indicating that IL-1β did contribute to the inhibition of insulin signaling (Fig. 6g) . Because Nlrp3 −/− , Pycard −/− or Casp1 −/− conditioned medium did not completely restore insulin-induced Akt phosphorylation, we hypothesized that TNF, which is present in Nlrp3 −/− , Pycard −/− or Casp1 −/− conditioned medium (Fig. 1i) , was also inhibiting insulin signaling (Fig. 6b,c) . Indeed, whereas blocking either IL-1β by anakinra or TNF by a neutralizing antibody partially restored insulin-induced Akt phosphorylation, blocking both IL-1β and TNF completely restored insulin-induced Akt phosphorylation, indicating that both of these cytokines inhibit insulin signaling (Fig. 6h) .
IL-1b and TNF cooperatively mediate insulin resistance
To assess the role of IL-1β in vivo, we injected mice with IL-1β, which decreased insulin sensitivity (Fig. 7a) . Meanwhile, IL-1β null (Il1b −/− ) mice fed with a HFD for 12 weeks did not show insulin resistance (Fig. 7b) . These results indicate that IL-1β is important in the development of insulin resistance in response to HFD. Given the observation that both IL-1β and TNF impaired insulin signaling in vitro (Fig. 6) , we sought to determine the individual effect of these two cytokines in insulin resistance in vivo. Administration of exogenous IL-1β (1 µg per kilogram body weight) elevated serum concentration of IL-1β as expected, and this was comparable between wild-type and Tnfa −/− mice (Fig. 7) . Administration of IL-1β also elevated serum TNF concentration in wild-type mice, in agreement with the known induction of TNF by IL-1β, but it did not elevate TNF in Tnfa −/− mice, as expected (Fig. 7) . In parallel, IL-1β administration induced more severe insulin resistance in wild-type mice than in similarly treated Tnfa −/− mice (Fig. 7c) . These results suggest that the absence of elevated TNF in Tnfa −/− mice partially improved insulin sensitivity during IL-1β administration. However, IL-1β also exerts TNFindependent effects to promote insulin resistance.
NLRP3 Inflammasome promotes insulin resistance in vivo
As an ultimate test, we studied whether the NLRP3-ASC-dependent IL-1β production contribute to insulin resistance in vivo. We measured blood glucose and insulin concentrations after 12 weeks of HFD. In the HFD-fed state, blood glucose (Fig. 8a, left) and insulin (Fig. 8a, right) were significantly lower in Nlrp3 −/− or Pycard −/− mice than in wild-type mice, suggesting that the absence of inflammasome components led to better maintenance of glucose homeostasis and higher insulin sensitivity, respectively. Glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) showed that after consumption of a regular diet, glucose metabolism and insulin sensitivity were similar in wild-type, Nlrp3 −/− and Pycard −/− mice (Supplementary Fig. 5 ). However, after 12 weeks of HFD, we observed a significant improvement in glucose metabolism and insulin sensitivity in Nlrp3 −/− (Fig. 8b,c) and Pycard −/− mice (Fig. 8d,e) .
To assess whether the insulin resistance effect of the inflammasome was attributable to the bone marrow or stromal compartment, we conducted bone marrow chimera experiments. The results showed that lethally irradiated wild-type or Pycard −/− hosts receiving Pycard −/− bone marrow cells showed more insulin sensitivity than those receiving wild-type bone marrow cells after 12 weeks of HFD (Fig. 8f) . Together, these findings support the initial working model (Supplementary Fig. 1 ) that inflammasome activation in the hematopoietic compartment impairs insulin signaling in insulin target cells through NLRP3-ASC. 
A r t i c l e s
We next examined the effect of inflammasome on insulin receptor signaling in the three key insulin target tissues, liver, adipose and muscle. Tissues were obtained from mice after insulin administration to assess insulin-induced phosphorylation of insulin receptor (IRβ), insulin receptor substrate-1 (IRS1) and, more distally, Akt. Pycard −/− mice had higher insulin signaling as shown by a 3.1-fold enhanced phosphorylation of IRβ, a 2.6-fold increase in the tyrosine phosphorylation of IRS1 and a 3.2-fold increase in Akt Ser473 phosphorylation (p-Akt) in liver tissue when compared to WT mice after 12 weeks of HFD (Fig. 8g) . Nlrp3 −/− mice showed a similar enhancement in p-Akt (Ser473) in the liver, adipose and muscle tissues, suggesting increased insulin signaling in the key target tissues (Fig. 8h) . The mRNA expression of inflammatory cytokines Tnfa and Mcp1 (Ccl2) was significantly lower in livers from Nlrp3 −/− mice (Fig. 8i) or Pycard −/− mice ( Fig. 8j and Supplementary Table 1 ) compared to those from wild-type controls. In summary, these in vivo animal experiments suggest that a myeloid-derived inflammasome complex promotes inflammatory cytokine production and insulin resistance in an HFD-induced model through reduction of insulin signaling.
One caveat is that the improved insulin sensitivity observed in Nlrp3 −/− mice after HFD might be associated with alternations in their basic metabolic parameters. To assess this, we subjected wild-type and Nlrp3 −/− mice to indirect calorimetric analysis using metabolic cages. The total body weights of male wild-type and Nlrp3 −/− mice on either regular diet or HFD were not different (Supplementary Fig. 6a) , which is consistent with a recent study 37 . Magnetic resonance imaging (MRI) analysis revealed similar proportions of fat and lean body mass in HFD-fed wild-type and Nlrp3 −/− mice (Supplementary Fig. 6b ). We observed no significant difference in food intake ( Supplementary  Fig. 6c ), water intake ( Supplementary Fig. 6d ) or activity (data not shown) between these two groups. Furthermore, nocturnal or diurnal measurements of total energy expenditure did not differ between these two groups (Supplementary Fig. 6e ). Therefore no significant difference was observed in the basic metabolic parameters of HFD-fed wild-type and Nlrp3 −/− mice.
DISCUSSION
Although several inflammatory cytokines, including IL-6 (ref. 38) and TNF 36 , have been indicated to be important inflammatory and prodiabetic mediators, anti-inflammation-based therapeutic strategies targeting these two cytokines in insulin resistance and T2D have been suboptimal. In contrast, a recent study indicates a promising therapeutic effect of anakinra in the treatment of T2D 6 . Our findings provide mechanistic insights regarding the activation of the inflammasome by saturated FFAs through an AMPK-ROS signaling axis. The inflammasome products then target host liver cells to reduce the IRβ and IRS1 tyrosine phosphorylation and more distal Akt serine phosphorylation that are essential for the proper biological effects of insulin.
In addition to the role described for the inflammasome activation, the role and mechanism of TNF in obesity and insulin resistance have been well described 35, 39 . TNF is induced in adipose tissue in conditions of obesity and contributes to the impairment of insulin signaling. Mechanistically, TNF induces serine phosphorylation of IRS1, resulting in impaired signal transduction between insulin receptor and the downstream phosphatidylinositol-3-OH kinase-Akt pathway that leads to insulin resistance. However, the endogenous molecule(s) that triggers TNF production remains largely unknown. We show here that IL-1β administration leads to elevated TNF and the lack of NLRP3 and ASC decreases Tnfa transcript under HFD. This finding agrees with other studies under conditions of regular diet that IL-1β signals through the adaptor molecule MyD88 to induce TNF expression. Therefore, the function of IL-1β in obesity-associated chronic inflammation and insulin resistance involves at least two mechanisms: (i) direct inhibition of insulin signaling in insulin target tissues by serine phosphorylation of IRS1 and (ii) indirect induction of insulin resistance by promotion of TNF generation.
The development of insulin resistance and T2D has been linked to increased availability of lipids and other nutrients due to overnutrition. Plasma concentrations of FFAs are elevated in insulin resistance and can predict T2D 32 . Recent studies have suggested that FFAs induce insulin resistance by participating in lipotoxic responses 40 and chronic inflammatory responses 1 , both of which promote insulin resistance and T2D. Overload of FFAs directly exerts a lipotoxic effect through an increase in intracellular lipid metabolites 41 . FFAs, particularly saturated fatty acids, show proinflammatory effects through their influence on innate immune cells such as macrophages. Previous studies have suggested that FFAs can engage TLRs and induce proinflammatory cytokine production 13, 14 . Our findings revealed that FFAs also exert their proinflammatory effects by triggering inflammasome activation and IL-1β cleavage and release. Inflammasome products are essential for the impairment of insulin signaling, consistent with the promising clinical findings on IL-1RA for insulin resistance and T2D 6 .
The uptake of FFAs by cells is mediated by several cell membrane proteins, such as CD36, fatty acid transport protein and plasma membrane fatty acid binding protein. FFAs then lead to the synthesis of triacylglycerol, which is a core component of lipid droplets 42 . Lipid metabolites including ceramide and diacylglycerol can activate NAPDH oxidase and enhance ROS generation 40 . FFA-enhanced ROS generation is negatively regulated by AMPK activation, which results in an increased β-oxidation of FFAs in mitochondria and decreased overall lipid load inside cells 20 . Consistent with these previous studies, this study finds that palmitate treatment induces ROS generation in a time-dependent manner, which is prevented by an ROS or NAPDH oxidase inhibitor. Enhanced ROS generation is attenuated by the presence of AMPK agonist, suggesting that AMPK upstream can inhibit ROS generation. We further identify AMPK as controlling autophagy upon LPS plus palmitate treatment. Thus, palmitatedecreased AMPK activity leads to defective autophagy and the accumulation of mitochondrial ROS, presumably by a deficiency in the clearance of dysfunctional mitochondria (mitophagy). As previous studies have shown that NAPDH oxidase-dependent generation of ROS is essential for NLRP3 inflammasome activation 17 , our findings indicate that FFA leads to inflammasome activation and IL-1β release through a newly identified AMPK-autophagy-ROS signaling pathway. This pathway is different from previously identified NLRP3 inflammasome activating mechanisms, such as those mediated by phagolysosomal pathway (pathogens and exogenous reagents) and P2X7R (ATP), as inhibiting these pathways did not alter inflammasome activation by palmitate-BSA. Conversely, the AMPK pathway is not involved in inflammasome activation by other conventional agonists of NLRP3 such as ATP, nigericin and alum. This supports the concept that the AMPK-ROS pathway is a more specialized route of inflammasome activation in response to palmitate.
In addition to ROS, another shared property of inflammasome activation and FFA stimulation that has not been previously appreciated is autophagy. As an intrinsic process that aims to provide energy and maintain cellular homeostasis, autophagy can be activated by several stimuli, such as bacterial and viral challenge 29 . Although controversy exists 43 , accumulating evidence, including the experiment shown in this report, supports the contention that TLR activation can induce autophagy 31, 44 , presumably owing to the energy demand of mounting of an immune response, including enhanced cytokine production and phagocytosis. Because autophagy is activated in response to nutrient-poor conditions, one would expect overnutrition to inhibit autophagy. Indeed, one report showed defective autophagy in obesity, which exacerbates insulin resistance 45 . Our study suggests a pathway whereby palmitate stimulation results in AMPK inhibition, leading to defective autophagy in myeloid cells, which has been shown to activate the inflammasome 25, 26 .
In summary, this work has studied how HFD induces an inflammatory IL-1β response, which then contributes to insulin signaling in key target tissues. Our data show that elevated fatty acid caused by an HFD can activate the NLRP3 inflammasome in macrophages by an AMPK-autophagy-ROS signaling pathway that has not been previously associated with the inflammasome. IL-1β induced by fatty acid prevents normal insulin signaling in insulin target tissues, ultimately resulting in insulin resistance.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
